Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Vical Incorporated (VICL)

Vical Incorporated (VICL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Vical Incorporated 10390 PACIFIC CENTER COURT SAN DIEGO CA 92121 USA

www.vical.com P: 858-646-1100

Description:

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs.

Key Statistics

Overview:

Market Capitalization, $K 15,441
Shares Outstanding, K 22,841
Annual Sales, $ 1,620 K
Annual Net Income, $ -16,250 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -4,580 K
60-Month Beta 0.31
% of Insider Shareholders 4.58%
% of Institutional Shareholders 34.10%
Float, K 21,795
% Float 95.42%

Growth:

1-Year Return -50.66%
3-Year Return -82.49%
5-Year Return -94.32%
5-Year Revenue Growth -79.02%
5-Year Earnings Growth 77.50%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 08/06/19
Earnings Per Share ttm -0.74
EPS Growth vs. Prev Qtr 47.62%
EPS Growth vs. Prev Year 50.00%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-7 on 09/03/19

VICL Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -29.46%
Return-on-Assets % -27.85%
Profit Margin % -1,003.09%
Debt/Equity 0.00
Price/Sales 11.29
Price/Cash Flow N/A
Price/Book 0.37
Book Value/Share 1.92
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar